SequelSEC

Yubo International Biotech Ltd YBGJ

Electromedical & Electrotherapeutic Apparatus · CIK 0000895464 · Fiscal year ends 1231

Revenue
$12.35K
Fiscal year ended 2026-06-30
Operating income
-$1.12M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$1Market value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.00Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue0.0×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Electromedical & Electrotherapeutic Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Operating margin-9614.6%4th
Net margin-8736.7%4th
Current ratio0.24x7th
Revenue YoY growth256.0%93th
Gross margin66.1%70th

Yubo International Biotech Ltd (YBGJ) reported revenue of $12.35K and net income of -$1.01M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Yubo International Biotech Ltd’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Electromedical & Electrotherapeutic Apparatus.

Income

Yubo International Biotech Ltd income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$12.35K
Cost of revenue$4.19K
Gross profit$8.16K
Operating income-$1.12M
Net income-$1.01M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income-$1.16M
Income tax expense$0
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Yubo International Biotech Ltd balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$11.99K
Total assets$672.27K
Current assets$583.10K
Total liabilities$3.33M
Current liabilities$3.33M
Total equity incl. NCI-$2.66M
Temporary (mezzanine) equityUnavailable
Inventory$24.80K
Accounts receivable$138.05K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

Yubo International Biotech Ltd cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$727.99K
Capital expendituresUnavailable
Investing cash flow-$79.90K
Financing cash flow$667.38K
Net change in cash$1.57K
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$112.85K

Derived

Yubo International Biotech Ltd derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross margin66.1%
Operating margin-9096.9%
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio0.18x
Revenue YoY growthUnavailable
Net margin-8157.3%
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open YBGJ in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.